Oxycodone/naloxone PR versus oxycodone PR in advanced cancer: A multi-centre randomised trial (ENhANCE trial)
Palliative Medicine · 2025
DOI: 10.1177/02692163251362563 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Palliative Medicine, 2025. Verfasst von Aaron K Wong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Oxycodone, Naloxone, Analgesics, Opioid, Cancer Pain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Mundipharma Pty Ltd.
Abstract (Originalsprache)
Background
Opioid-induced constipation is a common side effect of Oxycodone. Oxycodone/Naloxone Prolonged Release (OXN PR) mitigates opioid-induced constipation in non-cancer pain, however its evidence is limited in people with pain from advanced cancer.
Aims
To demonstrate analgesic non-inferiority, and superiority in reducing constipation for Oxycodone/Naloxone Prolonged Release (OXN PR) compared to Oxycodone Prolonged Release (Oxy PR).
Design
Multi-centre open-label randomised controlled trial comparing OXN PR to Oxy PR over 5 weeks. The primary aim was to demonstrate analgesic non-inferiority of OXN PR compared to Oxy PR. The secondary aim was to demonstrate superiority of constipation reduction in the OXN PR arm. Setting/participants: Participants with moderate-severe pain (⩾4/10) from advanced cancer were eligible.
Results
Thirty seven of planned 96 patients were recruited with the study stopping early due to enrolment challenges during the COVID-19 pandemic. Average pain was −1.5 points (95% CI −3.3; 0.4) favouring the OXN PR arm compared to Oxy PR at 5 weeks, meeting analgesic non-inferiority, defined as falling within a one point non-inferiority margin. The OXN PR arm demonstrated less constipation with a significantly lower Bowel Function Index score (−24.87 (95% CI 47.54; 2.21), p = 0.03) compared to Oxy PR. Adverse effect safety profile favoured OXN PR.
Conclusions
OXN PR is non-inferior to Oxy PR in analgesic effectiveness and superior in reducing constipation. These results indicate OXN PR as the choice of opioid preparation in advanced cancer. Future studies may explore adding naloxone to other slow and immediate release opioid preparations. Trial registry: Australian New Zealand Clinical Trials Registry Trial registration number: ACTRN12619001282178 URL of trial registry record: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377673&isReview=true
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
- Murdoch Children's Research Institute, Melbourne, VIC, Australia.
- Western Health, Australia.
- St Vincent's Hospital, Melbourne, VIC, Australia.
- Melbourne Health, Parkville, VIC, Australia.
ORCID-Profile: Aaron K Wong, Ruwani Mendis, Jennifer Philip, Brian Le
Förderung
- Mundipharma Pty Ltd
Zitieren
APA
Wong, A. K., Grobler, A., Mendis, R., Philip, J., & Le, B. (2025). Oxycodone/naloxone PR versus oxycodone PR in advanced cancer: A multi-centre randomised trial (ENhANCE trial). Palliative Medicine. https://doi.org/10.1177/02692163251362563
Vancouver
Wong AK, Grobler A, Mendis R, Philip J, Le B. Oxycodone/naloxone PR versus oxycodone PR in advanced cancer: A multi-centre randomised trial (ENhANCE trial). Palliative Medicine. 2025. doi:10.1177/02692163251362563
BibTeX
@article{Wong2025,
author = {Wong, Aaron K and Grobler, Anneke and Mendis, Ruwani and Philip, Jennifer and Le, Brian},
title = {Oxycodone/naloxone PR versus oxycodone PR in advanced cancer: A multi-centre randomised trial (ENhANCE trial)},
journal = {Palliative Medicine},
year = {2025},
doi = {10.1177/02692163251362563}
}
EUVIMED